

Flavia Niccolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7563903/publications.pdf>

Version: 2024-02-01

39
papers

1,861
citations

257450

24
h-index

289244

40
g-index

41
all docs

41
docs citations

41
times ranked

2871
citing authors

#	ARTICLE	IF	CITATIONS
1	Serotonin in Parkinson's disease. Behavioural Brain Research, 2015, 277, 136-145.	2.2	224
2	Diabetes mellitus and Parkinson disease. Neurology, 2018, 90, e1654-e1662.	1.1	158
3	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2015, 83, 115-121.	4.4	133
4	Imaging in Parkinson's disease. Clinical Medicine, 2016, 16, 371-375.	1.9	110
5	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain, 2015, 138, 3003-3015.	7.6	100
6	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain, 2015, 138, 3016-3029.	7.6	90
7	Cholinergic imaging in dementia spectrum disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1376-1386.	6.4	87
8	Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. Annals of Neurology, 2017, 81, 171-180.	5.3	77
9	Current status of PET imaging in Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1171-1182.	6.4	66
10	Neuroimaging in Huntington's disease. World Journal of Radiology, 2014, 6, 301.	1.1	60
11	Parkinson's Disease, Diabetes and Cognitive Impairment. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2016, 10, 11-21.	0.6	52
12	Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. Journal of the Neurological Sciences, 2018, 387, 220-227.	0.6	51
13	Cortical thinning across Parkinson's disease stages and clinical correlates. Journal of the Neurological Sciences, 2019, 398, 31-38.	0.6	51
14	Dopamine receptor mapping with PET imaging in Parkinson's disease. Journal of Neurology, 2014, 261, 2251-2263.	3.6	45
15	Molecular Imaging Markers to Track Huntington's Disease Pathology. Frontiers in Neurology, 2017, 8, 11.	2.4	44
16	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. Journal of Neurology, 2015, 262, 2653-2661.	3.6	41
17	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. Movement Disorders, 2018, 33, 1961-1965.	3.9	38
18	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37

#	ARTICLE	IF	CITATIONS
19	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2244-2254.	6.4	37
20	Recent imaging advances in neurology. <i>Journal of Neurology</i> , 2015, 262, 2182-2194.	3.6	33
21	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹ C]JMA107. <i>American Journal of Psychiatry</i> , 2016, 173, 714-721.	7.2	33
22	Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593.	1.1	30
23	The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. <i>Journal of Neural Transmission</i> , 2018, 125, 1217-1223.	2.8	26
24	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	6.4	26
25	Speech difficulties in early de novo patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 256-261.	2.2	26
26	Imaging in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 233-274.	2.0	21
27	PET in Multiple Sclerosis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e46-e52.	1.3	20
28	Molecular imaging of levodopa-induced dyskinesias. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 2107-2117.	5.4	18
29	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 185-196.	1.9	18
30	Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 131-172.	2.0	18
31	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1505-1515.	3.9	15
32	Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). <i>Journal of Neurology</i> , 2019, 266, 1203-1210.	3.6	14
33	Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. <i>Sleep Medicine</i> , 2018, 43, 25-30.	1.6	12
34	Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's patients. <i>PLoS ONE</i> , 2019, 14, e0214352.	2.5	12
35	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169.	2.2	11
36	Urinary dysfunction in early de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 939-940.	3.9	9

#	ARTICLE	IF	CITATIONS
37	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. BMC Neuroscience, 2019, 20, 55.	1.9	9
38	Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). Journal of Neural Transmission, 2020, 127, 51-59.	2.8	6
39	BG-12 and its potential for the prevention of relapse in multiple sclerosis. Degenerative Neurological and Neuromuscular Disease, 2012, 2, 119.	1.3	2